Baloxavir Marboxil

Category: pharmacological

Aliases: Xofluza

Pharmacological Mechanism

Influenza cap-dependent endonuclease (PA subunit) inhibitor — blocks viral mRNA synthesis. Single-dose oral therapy advantage over oseltamivir (5-day course). Reduced influenza A activity in some 2021 strains via PA I38T resistance mutation.

Half-Life (t½)

PO: 80h

Dosing Guidelines

• PO: Typical 40 mg (Range: 40–80 mg)

Target Organ Systems

• immune-hematologic

Pathways It Modulates

• Viral protease + neuraminidase (inhibitor) — influenza PA cap-dependent endonuclease

Chemical Identifiers

• PubChem CID: 124081896
• Formula: C27H23F2N3O7S
• Molecular weight: 571.55 g/mol
• InChIKey: RZVPBGBYGMDSBG-GGAORHGYSA-N
• SMILES: COC(=O)OCOC1=C2C(=O)N3CCOC[C@H]3N(N2C=CC1=O)[C@H]4C5=C(CSC6=CC=CC=C46)C(=C(C=C5)F)F

References

• PMID 35176206